Great report. Relatively new to NZC but under what circumstance...

First 9 Last

Share
Profile

Follow
Minelife

19 Posts.

04/08/17

14:32

Post #: 26295876
Share
Originally posted by leftenant ↑

Just sharing a report I helped put together on Nzuri Copper

www.lmtd.com.au

Summary:

Kalongwe Mine Development

11MT at 2.7%Cu and 0.27%Co, 2.29MT at 0.57%Co (13.29MT total)

80% oxide ore starting from surface, simple deposit geometry and low strip ratio.

85% ownership. Remaining 10% local partner GICC, and 5% DRC government.

Fully permitted in mining friendly area, close proximity to Ivanhoe project (<25km) and Kolwezi (45km)

Stage 1 mine: 1mtpa HMS concentrator

NPV10 of USD 176m (100% project) or 150m (pre-tax NZC share)

9 month payback period from production start

Capex of USD 39m estimated

Minelife currently 5 years, work underway to expand to 8 years (results due in 2019)

Potential stage 2 project: Heap Leach SX-EW

We estimate potential incremental NPV10 of USD 153m or 130m (pre tax NZC share)

Dependent on ongoing heap leach testing and power infrastructure coming online within 5 years for nearby Ivanhoe project

Definitive feasibility underway and due Q3 2017, mining to start Q3 2018

Reduced financing risk as key shareholder Tembo Capital (57.4%) is keen to see this through to production and cashflow

Exploration JV with Ivanhoe Mines “Fold and Thrust Belt JV”

334km2 of license in JV with Ivanhoe. NZC can earn up to 98% interest ( Ivanhoe can claw back up to 30%)

Potential for discoveries capable of supporting a standalone operation and smaller discoveries to convert to satellite pits that feed the central Kalongwe processing plant

Can expect to add roughly USD 80m to annual net cash flow to Stage 2 for every extra 1MT of 2% CuEq ore discovered during exploration.

Expand

Great report. Relatively new to NZC but under what circumstance would Ivanhoe Mines want to claw but their ownership of the JV FTB back up to 30%. ?
NZC Price at posting: 21.0¢ Sentiment: Buy Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

ASX Market Open: A weak performance on Wall Street keeps the Aussie bourse flat, as the world watches Iran | October 2, 2024

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

IRE

Iress runs 'hot' for Wealth Within's stock tips

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger